Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Mammary gland. Found 6 abstracts

Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homolog enriched in brain. Cancer Research. 2006 Jan;66(19):9461-6.
Adams GP, Simmons HH, Yuan Q, Marasco W, Mehta S. Anti-Mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer. 2005 Jul 08;:80 pp.
Adams GP, Horak EM, Weiner LM, Marks JD. Bispecific scFv antibody molecules capable of binding to different epitopes of EGFR protein family for diagnosis and treatment of cancer. 2004 Apr 04;:57 pp.
Hu YF, Russo IH, Russo J. Estrogen and human breast cancer. Handbook of Environmental Chemistry. 2002 Jan;3(Pt. M):1-25.
Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 2000 Jan;88(9):2154-63.
Russo IH, Russo J, Deluca G, Janssens JP. hCG therapy for the treatment of breast cancer. 2000 Dec 15;:61 pp.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Mammary gland

Mammary gland Human Prostate gland Diagnosis (cancer Bacteriophage Antitumor agents Radionuclides Ovary Cosmids Imaging (tumor unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (RIP (ribosome-inactivating protein)-antibody conjugated with unclassified) Epidermal growth factor receptors Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (HER4 unclassified) neu Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (bispecific scFv antibody mols capable of binding to different epitopes of EGFR protein family for diagnosis and treatment unclassified) Peptides Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (linker mullerian inhibiting substance receptor MISIIR immunoconjugate human cancer review estrogen breast cancer or a binding activity toward the hCG receptor for treatment of breast cancer) Drug delivery systems (compns contg hCG for treatment of breast cancer) Animal tissue Blood plasma Blood Transformation (estrogen and human breast cancer) hCG therapy for treatment of breast cancer) unclassified) Estrogen receptors Role: BSU (Biological study-BIOL (Biological study) (carcinogenicity of estrogens in causing breast cancer in relation to receptor-mediated hormonal activity and cytochrome P 450-mediated metabolic activation) protein having the biol activity of hCG and BSU (Biological study Gene Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (for antibody Epitopes hCG therapy in combination with an antiestrogen or a Type I interferon for treatment of breast cancer) unclassified) Antibodies and Immunoglobulins Role: BSU (Biological study-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (labeled Urine inhibitors Mammary gland (metastasis treatment of Carcinoma (cervix metastasis Antitumor agents (mammary gland Signal transduction (inhibitors unclassified) Hormone receptors Role: BSU (Biological study-BIOL (Biological study) (Mullerian-inhibiting hormone-type II PRP (Properties) Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (anti-MISIIR unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (momordins-antibody conjugated with Plasmids Intestine (colon Drug delivery systems (carriers Gene therapy synuclein breast ovarian carcinoma preneoplastic marker including toxicity) Estrogens Role: ADV (Adverse effect-BIOL (Biological study) (estrogen and human breast cancer) Antitumor agents (mammary gland carcinoma synucleins expressed in the most breast and ovarian carcinomas and in preneoplastic lesions of the ovary) Akt kinase pathway in breast cancer cell proliferation) hCG therapy for treatment of breast cancer in premenopausal and postmenopausal women) Tumor markers (g synuclein overexpression in preneoplastic lesions of the ovary) Phage display library Imaging (NMR unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (PAP (pokeweed antiviral protein)-antibody conjugated with unclassified) Toxins Role: BSU (Biological study-BIOL (Biological study) (antibody conjugated with BSU (Biological study Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (fragments-scFv anti-Mullerian inhibiting substance type II recep unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (TSC2 (tuberous sclerosis complex 2) Viral vectors estrogen tuberin Rheb mTOR kinase pathway breast cancer Rheb Phosphorylation Blood cell Drug delivery systems (immunoconjugates Lung anti-Mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer) Ovary (carcinoma unclassified) Toxins Role: BSU (Biological study-BIOL (Biological study) (diphtheria-antibody conjugated with b Salivary gland Pancreas Adoptive immunotherapy Ricins BSU (Biological study Proteins Role: BPR (Biological process)-unclassified)-BIOL (Biological study)-PROC (Process) (a--b--g-synuclein Protein sequences bispecific antibody scFv EGFR family member cancer diagnosis therapy Menopause (postmenopause Signal transduction (estrogen-induced activation of TSC Epidermal growth factor receptors Ligands unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (eIF-4E-BP1 (eIF-4E-binding protein 1)-phosphorylation of Scintigraphy unclassified) Growth factor receptors Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (erbB-3 Imaging agents cDNA sequences (anti-Mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer) site lacking Post-translational processing (proteolytic BSU (Biological study Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (bispecific unclassified) Toxins Role: BSU (Biological study-DGN (Diagnostic use)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (cytotoxins Genetic vectors Liposomes Peptide nucleic acids bispecific scFv antibody mols capable of binding to different epitopes of EGFR protein family for diagnosis and treatment of cancer) antibody conjugated with Drug delivery systems (prodrugs Lung (toxicity Plasmid vectors Chemotherapy (antibody conjugated with BSU (Biological study Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-unclassified)-DGN (Diagnostic use)-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (bispecific scFv antibody unclassified) Ribosomal proteins Role: BSU (Biological study-BIOL (Biological study) (S6 Imaging agents (NMR contrast cytoplasmic proteins expressed in the most breast and ovarian carcinomas and in preneoplastic lesions of the ovary) Cell proliferation Drug delivery systems (liposomes mTOR Labels Abrins Viral vectors (bispecific scFv antibody mols capable of binding to different epitopes of EGFR protein family for diagnosis and treatment of cancer) Diagnosis (immunodiagnosis of EGFR protein family for diagnosis and treatment of cancer) DNA sequences except adverse) Interferons Role: BAC (Biological activity or effector-BSU (Biological study-unclassified)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (a Testis unclassified) Estrogens Role: BSU (Biological study-BIOL (Biological study) (estrogen-induced activation of TSC Positron-emission tomography Drugs Linking agents carcinoma Uterus (cervix-treatment of inhibitors Mammary gland (neoplasm-metastasis Fusion proteins Cytotoxic agents magnetic Spheres (beads-antibody conjugated with Gamma ray (emitters or (MISIIR) immunoconjugates to detect and treat cancer) Samples (biol or biopsy Antitumor agents (mammary gland Molecules (effector Uterus (endometrium except adverse) Fusion proteins Role: BAC (Biological activity or effector-BSU (Biological study-unclassified)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (of LH-FSH-or TSH MAP Stomach Molecular cloning Uterus (cervix inhibitors Mammary gland (neoplasm PRP (Properties) Antibodies and Immunoglobulins Role: BPN (Biosynthetic preparation)-THU (Therapeutic use)-BIOL (Biological study)-PREP (Preparation)-USES (Uses) (single chain-Fv-anti-MISIIR except adverse) Estrogens Role: BAC (Biological activity or effector-BSU (Biological study-unclassified)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (antiestrogens Chemotherapy unclassified) G proteins Role: BSU (Biological study-BIOL (Biological study) (RHEB (Ras homolog enriched in brain) Animal cell pharmaceutical compn hCG breast cancer treatment Radiation (external beam Immunoassay (immunohistochem hCG breast cancer treatment Drug interactions (hCG therapy in combination with an antiestrogen or a Type I interferon for treatment of breast cancer) antibody conjugated with Pseudomonas (exotoxin BSU (Biological study Gonadotropin receptors Role: BPR (Biological process)-unclassified)-BIOL (Biological study)-PROC (Process) (ligand estrogen-induced activation of TSC inhibitors Mammary gland (carcinoma bispecific scFv antibody mols capable of binding to different epitopes aspirate Mammary gland (nipple Testis (treatment of
Last updated on Tuesday, July 07, 2020